Bone mineral density in thalassemia major patients from antalya, Turkey
Ibrahim Aslan, Duran Canatan, Nihal Balta, Gulizar Kacar, Cengaver Dorak, Ahmet Ozsancak, Nurgul Oguz, Ruya Cosan, Ibrahim Aslan, Duran Canatan, Nihal Balta, Gulizar Kacar, Cengaver Dorak, Ahmet Ozsancak, Nurgul Oguz, Ruya Cosan
Abstract
Aim. We assessed the bone mineral density and related parameters in nine adults, thirty-eight pubertal, prepubertal totally forty-seven patients with thalassemia major living in Antalya, Turkey. Materials and Methods. We measured height and pubertal staging in last five years by six-month intervals. Average ferritin and hemoglobin concentrations were calculated for last three years. The levels of hydroxyproline, calcium, phosphorus, and creatinine were measured in 24 h urine, and those of parathormone, IGF 1, osteocalcine, alkaline phosphatase, calcium, ionized calcium, magnesium, phosphorus, creatine, blood glucose, thyroid stimulating hormone, alanine transaminase, and aspartate transaminase were determined in serum, and also the bone mineral density was measured. Results. The average L1-L4 bone mass density was 27.1 ± 10.1 g cm(-2); the average bone mineral content was 0.65 ± 0.11 g. of the patients with a Z-score under 2.5. A moderate relationship was found between the bone mass density age and height. Subjects in low pubertal staging and short stature (<3% percentile) have significantly lower bone mass densities P < 0.001. Conclusion. he prevalence of osteoporosis is high in patients with thalassemia major, possibly related to delayed puberty.
Figures
References
- Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clinical Endocrinology. 1995;42(3):279–287.
- Soliman AT, El Banna N, Fattah MA, ElZalabani MM, Ansari BM. Bone mineral density in prepubertal children with β-thalassemia: correlation with growth and hormonal data. Metabolism. 1998;47(5):541–548.
- Wonke B, Hoffbrand AV, Bouloux P, Jensen C, Telfer P. New approaches to the management of hepatitis and endocrine disorders in Cooley’s anemia. Annals of the New York Academy of Sciences. 1998;850:232–241.
- Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L. Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatrica, International Journal of Paediatrics. 1997;86(4):342–346.
- Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, Aggellaki M, Pazaitou K, Vainas I. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcified Tissue International. 1999;64(6):481–484.
- Chatterjee R, Bajoria R. Osteopenia-osteoporosis syndrome in patients with thalassemia:understanding of type of bone disease and response to treatment. Hemoglobin. 2009;33(supplement 1):S136–S138.
- Kyriakou A, Savva SC, Savvides I, et al. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatric Endocrinology Reviews. 2008;6(supplement 1):116–122.
- Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. Journal of Osteoporosis. 2010;2010:7 pages.537673
- Ebina Y, Okada S, Hamazaki S, Toda Y, Midorikawa O. Impairment of bone formation with aluminum and ferric nitrilotriacetate complexes. Calcified Tissue International. 1991;48(1):28–36.
- Eyres KS, McCloskey EV, Fern ED, et al. Osteoporotic fractures: an unusual presentation of haemochromatosis. Bone. 1992;13(6):431–433.
- de Sanctis V, Pintor C, Gamberini MR, et al. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clinical Endocrinology. 1995;42(6):581–586.
Source: PubMed